NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVOKAMET is a fixed-dose oral combination tablet containing canagliflozin (an SGLT2 inhibitor) and metformin hydrochloride (a biguanide) approved in 2014 for type 2 diabetes. It combines two complementary mechanisms to improve glycemic control by enhancing urinary glucose excretion and reducing hepatic glucose production. This adjunctive therapy targets patients inadequately controlled on monotherapy.
$22MPart D
PeakStable
3.7 years to LOEProduct is in peak commercial maturity with $22M in annual Part D spending; brand team size likely stable but defending against competitive erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
Started Nov 2020
276 enrolled
Diabetes Mellitus
A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers
Started Aug 2008
16 enrolled
Healthy
Why This Matters for Your Career
Worked on INVOKAMET at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.